Monitoring of unfractionated heparin with the activated partial thromboplastin time: Determination of therapeutic ranges

Thrombosis Research

Volumn 107, Issue 5, 2002, Pages 235-240

  Van den Besselaar, A M H P ^a   Sturk, A ^b   Reijnierse, G L A ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c RIJNLAND HOSPITAL   (Netherlands)

Author keywords

Anti Xa; APTT; Therapeutic range; Unfractionated heparin

Indexed keywords

BLOOD CLOTTING FACTOR 10A; HEPARIN; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS;

ACCURACY; ARTICLE; BLOOD SAMPLING; CALCULATION; CALIBRATION; CONTROLLED STUDY; DRUG MONITORING; HUMAN; LABORATORY; MAJOR CLINICAL STUDY; MEASUREMENT; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; DOSE RESPONSE; METHODOLOGY; OBSERVER VARIATION; REGRESSION ANALYSIS;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HEPARIN; HUMANS; INDICATORS AND REAGENTS; OBSERVER VARIATION; PARTIAL THROMBOPLASTIN TIME; REGRESSION ANALYSIS;

EID: 0036761802     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00303-1     Document Type: Article

References (22)

1. Kitchen S., Preston F.E. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays. Thromb. Haemost. 75:1996;734-739.
2. Hirsh J. Heparin. N. Engl. J. Med. 324:1991;1565-1574.
3. Brill-Edwards P., Ginsberg J.S., Johnston M., Hirsh J. Establishing a therapeutic range for heparin therapy. Ann. Intern. Med. 119:1993;104-109.
4. Olson J.D., Arkin C.F., Brandt J.T., Cunningham M.T., Giles A., Koepke J.A.et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy. Laboratory monitoring of unfractionated heparin therapy. Arch. Pathol. Lab. Med. 122:1998;782-798.
5. Volles D.F., Ancell C.J., Michael K.A., Mullins D.M., Humphries J.E. Establishing an institution-specific therapeutic range for heparin. Am. J. Health-Syst. Pharm. 55:1998;2002-2006.
6. Lyon S.G., Lasser E.C., Stein R. Modification of an amidolytic heparin assay to express protein-bound heparin and to correct for the effect of antithrombin III concentration. Thromb. Haemost. 58:1987;884-887.
7. Van der Velde E.A. Orthogonal regression equation. Van den Besselaar A.M.H.P., Gralnick H.R., Lewis S.M. Thromboplastin calibration and oral anticoagulant control. 1984;25-39 Martinus Nijhoff Publishers, Boston.
8. Morin R.J., Richards D. Effect of freezing heparinized plasma on the activated partial thromboplastin time. Am. J. Clin. Pathol. 61:1974;823-827.
9. Van den Besselaar A.M.H.P., Meeuwisse-Braun J., Bertina R.M. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples. Thromb. Haemost. 63:1990;16-23.
10. Smythe M.A., Koerber J.M., Westley S.J., Nowak S.N., Begle R.L., Balasubramaniam M.et al. Use of the activated partial thromboplastin time for heparin monitoring. Am. J. Clin. Pathol. 115:2001;148-155.
11. D'Angelo A., Seveso M.P., D'Angelo S.V., Gilardoni F., Dettori A.G., Bonini P. Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Implications in heparin monitoring by APTT. Am. J. Clin. Pathol. 94:1990;297-306.
12. Van den Besselaar A.M.H.P., Meeuwisse-Braun J., Strebus A., Schaefer-van Mansfeld H., Witteveen E., Van der Meer F.J.M. Response of the activated partial thromboplastin time (APTT) to heparin is influenced by coagulometers. Thromb. Haemost. 74:1995;1383-1384.
13. Siegel J.E., Bernard D.W., Swami V.K., Sazama K. Monitoring heparin therapy. APTT results from partial- vs. full-draw tubes. Am. J. Clin. Pathol. 110:1998;184-187.
14. Adcock D.M., Kressin D.C., Marlar R.A. Effect of 3.2% vs. 3.8% sodium citrate concentration on routine coagulation testing. Am. J. Clin. Pathol. 107:1997;105-110.
15. Van der Meer F.J.M., Vos H.L., Rosendaal F.R. No indication for APTT screening in patients on oral anticoagulant therapy. Thromb. Haemost. 81:1999;364-366.
16. Van den Besselaar A.M.H.P., Bertina R.M. Laboratoriumcontrole van behandeling met heparine in hoge dosering: resultaten van een enquête in Nederland. Tijdschr. Ned. Ver. Klin. Chem. 14:1989;47-51.
17. Loeliger E.A., Broekmans A.W. Optimal therapeutic anticoagulation. Haemostasis. 15:1985;283-292.
18. Krulder J.W.M., Van der Meer F.J.M., Briët E., Meinders A.E. Monitoring heparin treatment with the APTT: the effect of methodological changes on the APTT. Neth. J. Med. 49:1996;13-18.
19. Levine M.N., Hirsh J., Gent M.et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch. Intern. Med. 154:1994;49-56.
20. Hull R.D., Raskob G.E., Rosenbloom D.et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch. Intern. Med. 152:1992;1589-1595.
21. Kitchen S., Theaker J., Preston F.E. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay. Blood Coagul. Fibrinolysis. 11:2000;137-144.
22. Eby C. Standardization of APTT reagents for heparin therapy monitoring: urgent or fading priority? Clin. Chem. 43:1997;1105-1107.